(12) **Translation of European patent specification**

(11) **NO/EP 4166539 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 207/267 (2006.01) ***C07D 401/12 (2006.01)***
A61K 31/4015 (2006.01) ***C07D 403/12 (2006.01)***
A61K 31/4025 (2006.01) ***C07D 403/14 (2006.01)***
A61P 31/14 (2006.01) ***C07D 497/04 (2006.01)***

Norwegian Industrial Property Office

(45)	Translation Published	2025.01.20
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.10.09
(86)	European Application Nr.	22198597.1
(86)	European Filing Date	2021.08.06
(87)	The European Application's Publication Date	2023.04.19
(30)	Priority	2020.09.03, US, 202063073982 P 2021.01.29, US, 202163143435 P 2021.04.02, US, 202163170158 P 2021.05.28, US, 202163194241 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated validation states	MA ; MD ; TN
(62)	Divided application	EP3953330, 2021.08.06
(73)	Proprietor	Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001-2192, USA
(72)	Inventor	OWEN, Dafydd Rhys, Cambridge, MA 02139, USA PETTERSSON, Martin Youngjin, Littleton, MA 01460, USA REESE, Matthew Richard, Groton, CT 06340, USA SAMMONS, Matthew Forrest, Cambridge, MA 02139, USA TUTTLE, Jamison Bryce, Cambridge, MA 02139, USA VERHOEST, Patrick Robert, Cambridge, MA 02139, USA WEI, Liuqing, Groton, CT 06340, USA YANG, Qingyi, Cambridge, MA 02139, USA YANG, Xiaojing, Groton, CT 06340, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS**

(56) References Cited:

WO-A1-2005/113580

ZHAI YANGYANG ET AL: "Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease", vol. 58, no. 23, 10 December 2015 (2015-12-10), US, pages 9414 - 9420, XP055841288, ISSN: 0022-2623, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01013> DOI: 10.1021/acs.jmedchem.5b01013

WANG YAXIN ET AL: "Inhibition of enterovirus 71 replication by an [alpha]-hydroxy-nitrile derivative NK-1.9k", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 141, 5 January 2017 (2017-01-05), pages 91 - 100, XP029949620, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2017.01.002
HALFORD BETHANY: "To conquer COVID-19, create the perfect pill", CHEMICAL & ENGINEERING NEWS (2021), 99(19), 20 May 2021 (2021-05-20), pages 28 - 31, XP055847761, Retrieved from the Internet <URL:https://cen.acs.org/pharmaceuticals/drug-discovery/covid-19-oral-antiviral-pill-candidates/99/i19> [retrieved on 20211005]

Patentkrav

1. Forbindelse ifølge en hvilken som helst av formlene Ih-1a, Ih-1b, Ih-1c, Ii-1a, Ii-1b, Ii-1c, Ij-1a, Ij-1b, Ij-1c, Ik-a, Ik-b og Ik-c:



Ih-1a ,



Ih-1b ,



Ih-1c ,



Ii-1a ,



Ii-1b ,



Ii-1c ,



Ij-1a ,



Ij-1b ,



Ij-1c ,



Ik-a ,



Ik-b og



Ik-c ;

hvor R^4 er valgt fra gruppen bestående av (C_1-C_6-alkyl)amino, eventuelt substituert med én til fem fluor, C_1-C_6-alkyl-C(O)NH-, eventuelt substituert med én til fem fluor, og C_1-C_6-alkyl-$S(O)_2NH$-, eventuelt substituert med én til fem fluor;

eller et solvat eller hydrat derav, eller et farmasøytisk akseptabelt salt av forbindelsen, solvatet eller hydratet;

for bruk som et medikament.

2. Forbindelse for bruk som et medikament, ifølge krav 1, hvor R^4 er valgt fra gruppen bestående av $CF_3C(O)NH$-, $CF_3S(O)_2NH$-, $CH_3C(O)NH$-, $CH_3CH_2C(O)NH$- og CF_3CH_2NH-; eller et solvat eller hydrat derav, eller et farmasøytisk akseptabelt salt av forbindelsen, solvatet eller hydratet.

3. Forbindelse for bruk som et medikament, ifølge krav 2, hvor R^4 er $CF_3C(O)NH$- eller $CF_3S(O)_2NH$-; eller et solvat eller hydrat derav.

4. Forbindelse for bruk som et medikament, ifølge krav 1, hvor forbindelsen er (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid med strukturen



eller et solvat eller hydrat derav.

5. Forbindelse for bruk som et medikament, ifølge krav 4, hvor forbindelsen er (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid med strukturen



6. Forbindelse for bruk som et medikament, ifølge krav 4, hvor forbindelsen er krystallinsk (1*R,2S,5S)-N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid.

7. Forbindelse for bruk som et medikament, ifølge krav 6, hvor forbindelsen er (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid, fast form 1, **karakterisert ved** et pulver-røntgendiffraksjonsmønster (Cu-strålingskilde, K-α-gjennomsnitt) inneholdende topper ved 7,6; 9,8; 11,4; 11,9; 12,7; 15,7; 15,8; 17,3; 17,8; 18,3; 18,9; 19,7; 19,9; 20,5; 21,0; 21,7; 22,2; 22,5; 23,1; 23,6; 24,7; 25,3; 27,0; 27,2; 27,9; 28,1; 29,5; 32,6; 35,7 og 37,0 °2-theta +/- 0,2°.

8. Forbindelse for bruk som et medikament, ifølge krav 6, hvor forbindelsen er (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid, fast form 4, **karakterisert ved** et pulver-røntgendiffraksjonsmønster (Cu-strålingskilde, K-α-gjennomsnitt) inneholdende topper ved 7,6; 9,8;

10,8; 11,2; 11,4; 11,4; 11,7; 12,0; 12,3; 12,7; 13,7; 14,9; 15,1; 15,9; 17,5; 18,0; 18,2; 18,5; 18,8; 20,0; 20,4; 20,7; 21,1; 21,6; 21,8; 22,3; 23,1; 23,4; 24,2; 24,9; 25,2; 26,1; 27,0; 27,2; 28,1; 28,9; 29,4; 29,5; 29,8; 30,0; 30,6; 30,8; 31,3; 31,8; 32,5; 32,8; 33,2; 34,4; 35,5; 35,6; 35,6; 36,0; 36,4; 37,1; 38,7; 39,4; 39,5 og 39,8 °2-theta +/- 0,2°.

9. Forbindelse for bruk som et medikament, ifølge krav 4, hvor forbindelsen er amorf (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid.

10. Forbindelse for bruk som et medikament, ifølge krav 4, hvor forbindelsen er (1*R*,2*S*,5*S*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-6,6-dimetyl-3-[3-metyl-*N*-(trifluoracetyl)-L-valyl]-3-azabisyklo[3.1.0]heksan-2-karboksamid, metyl-tert-butyleter-solvat.

11. Forbindelse for bruk som et medikament, ifølge krav 10, hvor forbindelsen er krystallinsk.

12. Forbindelse *N*-(metoksykarbonyl)-3-metyl-L-valyl-(4*R*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-4-(trifluormetyl)-L-prolinamid med strukturen



;

eller et solvat eller hydrat derav, for bruk som et medikament.

13. Forbindelse for bruk som et medikament, ifølge krav 12, som er *N*-(metoksykarbonyl)-3-metyl-L-valyl-(4*R*)-*N*-{(1*S*)-1-cyano-2-[(3*S*)-2-oksopyrrolidin-3-yl]etyl}-4-(trifluormetyl)-L-prolinamid.